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Abstract: Despite current advances in antibiotic therapy and vaccines, meningococcal   disease 
serogroup C (MDC) remains a serious threat to global health, particularly in countries in 
North and Latin America, Europe, and Asia. MDC is a leading cause of morbidity, mortality, 
and neurological sequelae and it is a heavy economic burden. At the individual level, despite 
advances in antibiotics and supportive therapies, case fatality rate remains nearly 10% and severe 
neurological sequelae are frequent. At the population level, prevention and control of infection 
is more challenging. The main approaches include health education, providing information to 
the public, specific treatment, chemoprophylaxis, and the use of vaccines. Plain and conjugate 
meningococcal C polysaccharide vaccines are considered safe, are well tolerated, and have been 
used successfully for over 30 years. Most high-income countries use vaccination as a part of 
public health strategies, and different meningococcal C vaccination schedules have proven to 
be effective in reducing incidence. This is particularly so with conjugate vaccines, which have 
been found to induce immunogenicity in infants (the age group with the highest incidence rates 
of disease), stimulate immunologic memory, have longer effects, not lead to hyporesponsive-
ness with repeated dosing, and decrease acquisition of nasopharyngeal carriage, inducing herd 
immunity. Antibiotics are considered a cornerstone of MDC treatment and must be adminis-
tered empirically as soon as possible. The choice of which antibiotic to use should be made 
based on local antibiotic resistance, availability, and circulating strains. Excellent options for a 
7-day course are penicillin, ampicillin, chloramphenicol, and third-generation cephalosporins 
(ceftriaxone and cefotaxime) intravenously, although the latter are considerably more expensive 
than the others. The use of steroids as adjunctive therapy for MDC is still controversial and 
remains a topic of debate. A combination of all of the aforementioned approaches is useful in 
the prevention and control of MDC, and each country should tailor its public health policy to 
its own particular needs and knowledge of disease burden.
Keywords: epidemiology, public health significance, vaccination strategies, disease 
management
Introduction
Despite current advances in antibiotic therapy and vaccines, as well as the availability of 
sophisticated intensive care, Neisseria meningitidis remains a major cause of meningitis 
and meningococcemia, and, less commonly, a cause of pneumonia, septic arthritis, 
pericarditis, and conjunctivitis, in hundreds of thousands of individuals worldwide 
each year.1–5 There are several issues that underline its importance. Meningococcal 
disease (MD) can be rapidly progressive and fatal in previously healthy individuals.6 
Also, it is a leading cause of morbidity and mortality in all age groups worldwide, 
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although young children and adolescents are at particular 
risk.7,8 Most cases are sporadic, but case cluster, outbreaks, 
epidemics, and pandemics have been reported in different 
regions of the world.5 It is common for survivors of MD to 
develop permanent sequelae, such as skin scarring, abnormal 
bone growth, limb loss and multiple amputations, hearing 
loss, cognitive deficits, visual impairment, educational dif-
ficulties, developmental delays, motor nerve deficits, seizure 
disorders, and behavioral problems.8–11
Six major disease-causing N. meningitidis serogroups 
(A, B, C, W-135, X, and Y) are responsible for nearly 
90% of disease worldwide.1,7,12,13 MD serogroup C (MDC) 
remains a serious threat to global health, ranking as the 
second most common serogroup causing disease in North 
and Latin America, Europe, and Asia,14–17 exceeded only by 
MD serogroups A and B. The purpose of this review is to 
discuss the current epidemiology, management, and public 
health implications of MDC. Experiences with available 
meningococcal C vaccines will also be reviewed, and their 
potential public health impact will be considered.
Epidemiology
A remarkable characteristic of MD is its complex, fluid, 
and changing epidemiology. It has major cyclical incidence 
fluctuations in endemic disease and epidemics, as well as 
a highly regional serogroup distribution.1,12,18 Because of 
this, reliable surveillance systems are essential for adequate 
monitoring of local epidemiology and disease burden, as 
well as monitoring of the impact of control and prevention 
measures. The reporting of clinically diagnosed MD to local 
public health authorities is legally mandatory in most parts 
of the world.1,19,20 Among the variety of methods for con-
ducting meningococcal surveillance,21 the gold standard is 
laboratory-based surveillance, mostly used in countries with 
high economic resource, where high-standard laboratories are 
able to identify bacteria in cerebrospinal fluid (CSF), blood, 
or other normally sterile body fluids by culture or polymerase 
chain reaction (PCR).1 In some countries, non-culture-based 
approaches such as latex agglutination and counterimmuno-
electrophoresis are frequently used to supplement cultures.22 
Since the mid-1990s, PCR-based approaches have increas-
ingly been used to identify patients with meningococcal 
infection.23 In resource-poor countries, where laboratory 
facilities are scarce or inaccessible, surveillance is based on a 
simple case definition, and only a modest proportion of cases 
may be confirmed using laboratory methods.24,25
N. meningitidis is a Gram-negative diplococcus classi-
fied into 13 serogroups based on the immunogenicity and 
structure of the polysaccharide capsule. Further classifica-
tion into serosubtype, serotype, and immunotype is based 
on class 1 outer membrane proteins, class 2 or 3 outer 
membrane proteins, and lipopoly(oligo)saccharide structure, 
respectively.5,8
Humans are the only natural host for meningococcus, 
a frequent member of human pharynx and upper respiratory 
flora.26,27 Somewhere between 8% and 25% of the general 
population may be asymptomatic carriers, translating to 
hundreds of millions of carriers worldwide. Adolescents 
are considered a major reservoir. The principal route of 
meningococcal transmission is person-to-person contact via 
respiratory droplets or oral secretions from an asymptomatic 
carrier or individual with invasive disease. A contaminated 
vehicle (eg, a cigarette, food utensils, or drink bottle) may 
also spread bacteria, but the risk of such transmission is 
very low. The disease incubation period can vary from 
1 to 10 days, but the average is 2–4 days.5,26 The patient 
remains infectious for as long as meningococci are present 
in   respiratory/oral secretions, or for 24 hours after initiation 
of effective antibiotic treatment.
In a minority of exposed individuals (,1%), N.   meningitidis 
penetrates the nasopharyngeal mucosa, reaches the blood-
stream, and progresses to invasive disease.5,8,26 The ability 
to cause invasive disease depends on environmental factors, 
meningococcal virulence factors, and lack of a host protective 
immune response. The most common known risk factors for 
MD include active and passive smoking,8 travel to epidemic 
areas,27 crowding, exposure to low humidity, dust and coin-
fections, deficiencies in terminal complement components, 
asplenia, and deficiencies in mannose-binding lectin.28–30 
Other main factors depend on the agent, such as hypervirulent 
lineages (eg, serogroup C ST-11 complex/ET-37 complex 
and ST-8 complex/cluster A4).1
Although MD occurs throughout the year, incidence peaks 
in late winter and early spring.26 MD affects persons of all 
ages, but the highest rates are seen in infants and children 
under 4 years old and in adolescents.5 In the United States 
and Canada, the incidence has fluctuated between approxi-
mately 0.5 and 1.5 cases per 100,000 population per year.2,31 
In both   countries, serogroup C ranks the second most com-
mon   serogroup   causing disease after serogroups Y and B, 
respectively.1 Reporting from Latin America and the Caribbean 
has been characterized by marked differences from country 
to country. The overall incidence of MD varied per year from 
under 0.1 to 2.0 cases per 100,000 population.   Serogroups B 
and C are responsible for the majority of reported cases, but 
the emergence of serogroups W-135 and Y has been reported in 
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some countries.32,33 The African “meningitis belt” experiences 
periodic and large epidemics of serogroup A MD, showing the 
highest incidence of any region in the world.1 The epidemiol-
ogy of MD is well characterized in most European countries, 
although less information is available from in the eastern. 
The vast majority of cases are caused by serogroup B and C 
strains, and overall incidence of laboratory-confirmed disease 
is nearly 1.0 case per 100,000 population.34 The epidemiology 
of MD in much of Asia is likely to be highly heterogeneous 
and incompletely understood, in part because of the absence 
of surveillance in many countries, poor bacterial detection 
methods, and social and health care barriers to disease report-
ing.19 With the exceptions of Mongolia (13.0 cases per 100,000 
population)35 and China (2.1 cases per 100,000 population),36 
most Asian countries have reported rates lower than 1.0 cases 
per 100,000 population.19 Serogroup C is playing an increasing 
role in Asia; since 2002, serogroup C has become established 
in some provinces of China, where it has been responsible for 
local outbreaks.1,19,36 Serogroup C also plays a significant role 
in disease in Singapore.19 In Australasia, the epidemiology of 
MD follows the pattern seen in other industrialized nations. 
In the mid-1990s, Australia observed increases in incidence 
rates of MDC; in New Zealand, the incidence increased mark-
edly because of the emergence and spread of a ST-41/44 clonal 
complex/lineage 3 serogroup B clone.1
The case fatality rate in North America, Europe, and 
other high-income countries is nearly 8%, but the rate can 
be higher than 20% in resource-poor countries.1 The largest 
MDC   epidemics reported by the World Health   Organization23 
between 1970 and 1996 occurred in Brazil (São Paulo, 
1971–1972),   Vietnam (Ho Chi Minh City, 1977), and 
Burkina Faso   (Diapaga, 1979). Case clusters and outbreaks 
were seen in Canada and the US (1992–1993) and in Spain 
(1995–1997).37–39
Public health
From the perspective of public health, dealing with MD is a 
very challenging situation. This much-feared disease is fre-
quently a source of community and political concern, often 
receiving a high level of media attention. In many regions 
of the world, MDC is responsible for unexpected outbreaks 
and large epidemics, also causing high mortality as well as 
permanent and severe physical and neurological sequelae in 
survivors, with a substantial burden of disease.40
The main lines of public health against MDC are pre-
vention (before a case occurs) and control (after a case is 
diagnosed). In most countries the government is responsible 
for public health measures, including health promotion, and 
health service administration; in some countries the private 
sector and nongovernmental organizations also contribute.
One of the most important preventive actions toward 
MDC is to raise awareness among the population and health 
professionals. Information about the disease should be avail-
able for the community, particularly information regarding 
the main signs and symptoms and the importance of seeking 
early medical attention.41 Public health system policies should 
ensure that cases are referred early to hospital, receiving 
opportune and adequate medical attention. Also, policies 
must ensure there are efficient surveillance and response 
systems in place, allowing a prompt and timely diagnosis 
and reporting, endorsing control activities for close contacts 
of the cases.
In prevention of MDC, the striking regional variability in 
disease emphasizes the need for country-specific approaches 
to vaccine prevention.39 As well as this regional variability, 
the burden of MDC still remains unknown for many parts 
of the world because of inadequate surveillance, severely 
hampering the implementation of appropriate prevention 
strategies. Suitable surveillance of populations – especially 
those at high risk such as infants and teenagers,39,41,42 unprivi-
leged populations and ethnic minorities, and travelers43 – is 
essential for implementation of an appropriate prevention 
policy.
Over the past decade, substantial advances in meningo-
coccal vaccine development have occurred, and much has 
been learned about prevention from countries that have incor-
porated those vaccines into their immunization   programs. 
For countries with meningococcal vaccination policies, 
research on vaccine effectiveness and impact, including 
indirect effects, is crucial for informing policy decisions. 
Each country should tailor meningococcal vaccination 
policy according to their particular needs and knowledge of 
disease burden.
The introduction of new vaccines is an increasingly com-
plex and political process inevitably prone to controversy. 
Cost-effectiveness economic analysis of vaccination strate-
gies is essential and provides a framework for evaluation 
of such strategies, supporting their benefit.44 Commercial 
development of new vaccines by pharmaceutical companies 
tends to develop those products for which there is a big 
demand in the industrialized world.45
Most developed countries have introduced meningo-
coccal C vaccination into their national immunization 
programs, because vaccination has been demonstrated to 
be the most successful prevention strategy for confronting 
MDC.   Bivalent (A, C, and BC), trivalent (A, C, W-135), 
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and quadrivalent (A, C, Y, W-135) polysaccharide vaccines 
have already been licensed and made available13,46 for some 
time, but recent serogroup C conjugate vaccines confer 
immunologic advantages over polysaccharide vaccines, 
including the ability to induce a herd immunity effect and to 
stimulate immunologic memory.46 The use of these vaccines 
by public health decision makers has been recommended by 
the World Health Organization.45,47
Different meningococcal C vaccination schedules have 
proven to be effective in reducing incidence.48 In the United 
Kingdom (UK), all childhood immunizations and nation-
ally recommended immunizations for adults are provided 
free.45 Other countries, industrialized and nonindustrialized, 
also provide free vaccination to the general population.45,49 
In 1999, the UK was the pioneer in including serogroup C 
conjugate vaccines in childhood vaccination schedules.50 
Other industrialized countries in Europe, North America, 
and other regions where MDC is prevalent44,45,51–53 have also 
included serogroup C conjugate vaccines in public health 
policy, decreasing incidence rates of the disease   significantly. 
Among Latin American countries, Brazil is the only   country 
that has begun to introduce the serogroup C conjugate 
vaccine into the routine immunization schedule.46,32 Dur-
ing an MD epidemic, due to serogroups C and B, Cuba, 
implemented a high-coverage mass vaccination campaign 
in 1979, using a commercially available polysaccharide AC 
vaccine, achieving a substantial decrease in the incidence 
due to serogroup C. In the late 1980s a high-coverage mass 
vaccination was arranged in Cuba with meningococcal BC 
vaccine   (VA-MENGOC-BC®) obtained by the Finlay Institute 
in Havana, Cuba. This vaccine is the first of its type in the 
world – that is, safe, effective, and commercially available for 
preventing MD caused by serogroup B, while also efficiently 
preventing serogroup C.53 Since 1991, this vaccine has been 
successfully used in the Cuban routine childhood two-dose 
vaccination schedule.54 The incidence of disease caused 
by the epidemic strain (B:4:P1.19,15) has been reduced 
significantly, and there is a total absence of autochthonous 
cases due to   serogroup C, demonstrating the impact of this 
intervention.49,53,54 Subsequent molecular studies55 have 
shown the significant reduction of the frequency and diver-
sity of hypervirulent clonal complexes, also affecting the 
genetic composition of the carrier-associated meningococcal 
isolates after vaccination.
In East Asia and the southern Pacific, polysaccharide 
and conjugate serogroup C vaccines are available but are 
not often used as a part of routine immunization sched-
ules.46 In China, polysaccharide AC vaccine has been used 
to prevent MDC epidemics.56 New Zealand does not include 
serogroup C vaccine on their immunization program at the 
present time, considering the very low incidence of disease 
(0.48 cases per 100,000 population).57
Nonvaccination of population may lead to pockets of 
susceptible individuals in a population, increasing the risk 
of disease, and, at some point, sporadic cases, and the risk 
of potential outbreaks or epidemics. Therefore, an efficient 
surveillance system is required to detect any changes of 
disease incidence in a timely manner and to put into action 
the most appropriate prevention and control strategy.
On the other hand, one of the most important public 
health actions after identifying a case of MD is to prevent 
secondary cases among the patient’s close contacts, through 
chemoprophylaxis and efficient surveillance.58–61 The defini-
tion of intimate contact is not very accurate and it can include 
a large number of people.62 This concept should refer to all 
people who have had prolonged (8 hours or more) and close 
(within 3 feet) contact with the patient or who have been 
directly exposed to oral secretions (face-to-face contact, 
mouth-to-mouth resuscitation, kissing, or management of 
an endotracheal tube) of the patient within 1 week before 
the onset of symptoms until 24 hours after appropriate anti-
microbial therapy has been initiated. Such persons typically 
include members of the patient’s household or the patient’s 
roommates, persons at a child-care center, and others who 
have had prolonged exposure to the infected patient.58
Although the risk to contacts may be low, the highest 
absolute and relative risk is to people who live in the same 
household as the MD patient,41 particularly those who share 
bedrooms.58 The aim of chemoprophylaxis is to reduce the 
risk of disease directly by eradicating nasopharyngeal car-
riage of meningococci from any carrier who may be in the 
network of contacts close to each index case.40,59,60 Therefore, 
chemoprophylaxis should be offered to close contacts of 
cases, irrespective of vaccination status.59,60
Most approaches to chemoprophylaxis include a short 
course of antibiotics such as rifampicin (10 mg/kg body 
weight every 12 hours orally in children; 600 mg daily for 
2 days in adults) or, as an alternative, ciprofloxacin (500 mg 
orally once) or ceftriaxone (125 mg once intramuscularly 
in children; 250 mg once intramuscularly for those aged 
15 years or older).58–61 Ideally, chemoprophylaxis should 
be started within 24 hours after the index case has been 
identified, although diminishing levels of benefit may still 
be realized even with delays of up to 2 weeks.58,61
Despite heavy community pressure to “do something” 
immediately in response to a death from MD,   epidemiological 
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criteria should prevail in reaching a decision on whether or not 
to advise chemoprophylaxis and postexposure   vaccination. 
Immunization must be considered as a component of 
acute care in the setting of newly diagnosed infection, and 
  serogroup C meningococcal vaccine should be offered to close 
contacts.57,59,63 The rationale for vaccination is to reduce the 
ongoing risk of invasive disease in close contacts.60
The effectiveness, efficiency, and impact of health actions 
or interventions are essential in evaluation of health policy. 
The full value of epidemiological research is only realized 
when it is translated into health policy and the subsequent 
planning and implementation of effective prevention and 
control programs.
Previous considerations illustrate different strategies 
and the complexity involved in the judgment and selection 
of the most adequate strategy on public health. The health 
policy should consider current epidemiology of disease, 
immunogenicity, and antibody protection persistence in 
high-risk groups after immunization, vaccine effectiveness, 
cost-effectiveness, and the costs and benefits of different 
strategies. Results of these strategies should be monitored 
systematically.
Vaccination strategies
Available meningococcal C vaccines
Primary prevention of MD is essential for several reasons. 
The clinical presentation may be fulminant, with no oppor-
tunity for antibiotics to influence the course of the disease. 
Incidence rates of antibiotic-resistant strains are now increas-
ing and chemoprophylaxis of contacts during outbreaks is 
a complex and often unsuccessful public health measure. 
There are a range of vaccines available to prevent MDC: 
plain polysaccharide C vaccines, conjugate polysaccharide 
C vaccines, and a plain polysaccharide C + outer membrane 
vesicle of serogroup B vaccine.
Polysaccharide serogroup C vaccines
The first polysaccharide vaccines, developed approximately 
30 years ago, contain purified capsular polysaccharides of 
N. meningitidis. The AC bivalent vaccines and the quadriva-
lent A, C, W-135, and Y vaccines are shown in Table 1.
After being administered as part of mass vaccination 
programs to millions of persons, including military personnel, 
civilians, and travelers to areas of the world with endemic 
disease,64 meningococcal polysaccharides vaccines (bivalent 
A and C, quadrivalent A, C, Y and W-135) are considered 
safe and well tolerated. Pain and redness at the injection site 
are the most commonly reported adverse events (up to 40%). 
These local reactions are typically of mild severity and last 
for 1–2 days. Transient low-grade fevers (.38.4°C) occur 
in less than 1% of immunized persons. Severe reactions are 
uncommon, consisting of wheezing or urticaria in an esti-
mated 1.0 per 1 million doses, or anaphylaxis in ,1.0 per 
1 million doses. There are also rare reports of Guillain–Barré 
syndrome or other neurologic disorders such as optic neuritis, 
paresthesia, or convulsions with onset temporally associated 
with vaccination. In most of the reported instances, multiple 
injections of different vaccines were given to the patients, so 
the role of meningococcal vaccination is uncertain.65,66
The main disadvantages of serogroup C polysaccharide 
vaccines are the limited or lack of immune response in young 
children and that there is no durable immunologic memory: 
they do not stimulate T lymphocytes or induce immunologic 
memory.66 Serum antibody levels decline significantly in 
infants and children under 5 years of age, but in healthy adults 
antibodies can still be detected after 10 years. However, 
clinical protection wanes over time in all age groups.2,64,66,67 
Additionally, those vaccines have no or limited impact on 
nasopharyngeal carriage and, therefore, do not appear to 
contribute to herd immunity.65
The immunogenicity of serogroup C polysaccharide 
vaccines is age related, because the bactericidal activity 
of antibodies elicited by vaccination in children aged from 
Table 1 Available serogroup C meningococcal vaccines
Vaccine Serogroups Available vaccines
Polysaccharide2 A, C, w-135,  
Y (MPSv4)
Menomune®,  
ACwY vax®,  
Mencevax®
A, C Mengivac®, AC vax®, 
polysaccharide  
meningococcal  




C Menjugate®,  
Meningitec®,  
Neisvac-C®




Polysaccharide C + outer  
membrane vesicle  
of serogroup B strain specific53
C and B vA-MENGOC-BC®
Notes: Menomune and Menactra are registered trademarks of Sanofi Pasteur; ACWY 
vax, Mencevax, AC vax, and Menitorix are registered trademarks of GlaxoSmithKline; 
Mengivac is a registered trademark of Aventis Pasteur; polysaccharide meningococcal 
A and C vaccine is produced by Bio-Manguinhos, which fills the vaccine using bulbs 
manufactured at the Finlay Institute, Havana, Cuba; vax-Men-AC and vA-MENGOC-
BC  are  registered  trademarks  of  the  Finlay  Institute;  Meningitec  is  a  registered 
trademark of wyeth; Neisvac-C is a registered trademark of Baxter Healthcare.63
Abbreviations: Hib, Haemophilus influenzae type B; MCv4, quadrivalent meningococcal 
conjugate; MPSv4, quadrivalent meningococcal polysaccharide.
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18 months to 5 years may be disproportionately lower than 
that elicited in older children and adults68,69 and may decline 
to baseline within 1 year.70 The induction of immune hypo-
responsiveness to a subsequent exposure to serogroup C 
polysaccharide has been observed in studies of immunized 
infants,70 toddlers,71,72 and adults.73–75
The effectiveness of serogroup C polysaccharide vaccines 
in young children during a major group C epidemic in São 
Paulo76 was 12% (95% confidence interval (CI): −55, 62) for 
children aged 2 years, but it was 83% among US military 
recruits at high risk of acquiring MD.77
On the other hand, the effectiveness of serogroup C 
  polysaccharide vaccines estimated as part of postlicensure 
studies in Gregg County, Texas, was 85% among persons 
aged 2–29 years (95% CI: 27, 97) and 93% for children 
aged 2–5 years (95% CI: 12, 99).78 In Quebec, Canada, 
after 1.6 million of doses administered to persons aged 
between 6 months and 20 years, vaccine   effectiveness 
estimated for children under the age of 2 years was 
  negative; for children aged 2–9 years, vaccine effective-
ness was 41% (95% CI: −106, 79). Among persons aged 
5–20 years,   during the first 2 years of follow-up, efficacy 
was 65% (95% CI: 20, 84), but it dropped to 0% between 
3 and 5 years after vaccination (95% CI: −5, 65).79
Conjugate serogroup C vaccines
Conjugate serogroup C vaccines were introduced at the end of 
the 1990s and represent a major advance compared with plain 
polysaccharide vaccines, overcoming the shortcomings of 
these vaccines by converting the polysaccharide into a T-cell-
dependent antigen. They were developed by covalently 
binding highly immunogenic protein carriers to saccharide 
antigens (Table 1). This technique improves immunogenic-
ity in infants (the age group with the highest incidence rates 
of MD), stimulates immunologic memory, provides longer 
effects, does not lead to   hyporesponsiveness with repeated 
dosing, and can decrease acquisition of nasopharyngeal car-
riage, thereby possibly inducing herd immunity.67
With regard to prior polysaccharide vaccination effect 
on antibody response, it was noted that titer, serum bacteri-
cidal antibody response and duration was lower in the adults 
who were vaccinated previously with plain serogroup C 
  polysaccharide vaccine.80,81
In the UK, prelicensure safety studies of conjugate 
serogroup C vaccines reveal transient headache of mild to 
moderate severity as the most commonly reported adverse 
event, with the highest rate (12%) in the first 3 days after 
vaccination. Headache was reported more frequently in 
secondary school than in primary school children, and more 
frequently in girls than in boys. Local reactions at the injec-
tion site consisted mostly of pain, tenderness, and occasional 
redness. These tended to be of mild to moderate severity, 
were maximal on the third postvaccination day, and typically 
resolved within a day. Local reactions were more common 
after diphtheria toxoid or diphtheria toxoid-tetanus toxoid 
booster vaccination than conjugate serogroup C vaccination. 
Preexisting allergies did not appear to affect reactogenicity.82 
Postlicensure passive surveillance through reports of adverse 
vaccine events from health professionals to the UK Medicines 
Control Agency/Committee on Safety of Medicines indicated 
a rate of one adverse event per 2875 doses of conjugate 
  serogroup C vaccines which consisted of transient headache, 
pyrexia, dizziness, or local reaction. Anaphylaxis was reported 
at a rate of one per 500,000 doses distributed. While some new 
reactions to conjugate serogroup C vaccines were identified 
(such as headache, nausea, vomiting, abdominal pain, and 
malaise in all age groups), these were generally not serious 
and the risk-benefit analysis was overwhelming.64
In November 1999, conjugate serogroup C vaccination 
was introduced in the UK for infants and 15- to 17-year-olds, 
the two age groups with the highest risk of mortality from 
MDC. The adolescents were given one dose and the infants 
were given three doses at 2, 3, and 4 months of age along 
with their routine primary immunization. From mid-January 
2000 onward, catch-up immunization was done with two 
doses in infants aged 5–11 months and one dose in toddlers 
aged 12–23 months. Vaccination of 2- to 14-year-olds with a 
single dose was completed by late 2000.52 Population-based 
active surveillance monitored age-specific and capsular 
group-specific incidences of disease and estimated vaccine 
coverage. Within 12–18 months after introduction of group 
C vaccination, there was a marked decline in the number of 
cases and number of deaths caused by MDC in the age groups 
targeted for immunization.52,83 For all vaccinated groups, 
  vaccine effectiveness was 90% during the first year, but it had 
declined by 1–4 years after vaccination.52,83 This was more 
marked in infant than in toddlers. Toddlers, with one dose, 
showed effectiveness of 61% (95% CI: −327, 94).84 So far, 
the magnitude of the loss of protection in children and tod-
dlers at 1–4 years after immunization is uncertain.
In 1995 an increase of the MDC incidence associated with 
phenotype C:2b:P1.2.5 was observed in Spain. As a public 
health response to this, a mass vaccination campaign with 
polysaccharide vaccine was initiated in most of the country 
(1996–1997), reducing the number of cases caused by this 
serogroup.85,86 Two years after the mass   vaccination   campaign, 
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effectiveness began to decrease, with the number of cases 
rising in all age groups. As a result, the health authorities 
decided to include the new and available meningococcal 
C conjugate vaccine in the routine vaccination schedule by 
September 2000, as well as carrying out a mass vaccination 
campaign,86 achieving a significant decrease of MDC inci-
dence.85 Vaccine effectiveness estimates of 98% (95% CI: 
96, 98) declined to 78% (95% CI: 3, 95) beyond 1 year.87 
Postvaccination monitoring of both epidemiological evolu-
tion of MD and long-term effects, show cases caused by 
B:2a:P1.5 probably originated from virulent strain C:2a:P1.5, 
suggesting that capsular switching by exchange of genetic 
material encoding the polysaccharide capsule might have 
occurred.85
The Netherlands commenced immunization in 2002 with 
a single dose at 14 months of age, with a catch-up campaign 
from 1 to 19 years of age up to April 2006. No vaccine fail-
ures were detected, and the number of MDC cases declined 
from 276 in 2001 to only four in 2005.88 The decrease was 
observed even in those not targeted, and data were consistent 
with induction of herd immunity.
Control of disease may be more dependent on decrease 
carriage in the population and herd immunity generated 
by catch-up campaigns than of persistence of protective 
immunity provided by vaccine. Effectiveness on decreas-
ing meningococcal carriage after 1 year was 66%, and there 
was no evidence of increase in carriage in other capsular 
groups.89,90 For countries using conjugate serogroup C 
vaccines, close surveillance of replacement and capsular 
switching from C to B is required.91 Those concerns were 
not detected in the UK.92,93
In 2005, a quadrivalent meningococcal conjugate vaccine 
(MCV4) for serogroups A, C, W-135, and Y (Menactra®, 
Sanofi Pasteur, referred to herein as MCV4) was licensed 
in the United States for persons aged 11–55 years.94–96 As 
was the case with the monovalent serogroup C conjugate 
vaccines, the low incidence of MD in North America and 
Europe precluded performing an efficacy trial, and efficacy 
of the MCV4 vaccine was inferred from immunogenicity 
data. In these studies, MCV4 vaccine elicited noninferior 
serum bactericidal antibody responses as compared with 
the respective responses of controls given the US-licensed 
meningococcal quadrivalent polysaccharide vaccine 
(  MPSV4).97,98 For both vaccines, 97%–100% of subjects 
achieved serum   bactericidal titers against all four capsular 
groups. In prelicensure studies, MCV4 vaccine was safe and 
well tolerated.96,97,99 In randomized studies, low-grade fevers 
($38°C) were more common after MCV4 than MPSV4 
vaccination (5.1% versus 3.0%, respectively, in immunized 
adolescents, P , 0.05; 1.5% versus 0.5% in adults P , 0.05). 
Less than 5% of MCV4- or MPSV4-vaccinated subjects 
experienced serious systemic reactions (defined as high 
fevers; or headache, fatigue, malaise, chills or arthralgia 
requiring bed rest; or anorexia; or three or more episodes of 
vomiting; or five or more episodes of diarrhea; or the presence 
of rash or seizures). Local reactions were more common after 
MCV4 than MPSV4 vaccination, which likely reflects the 
presence of diphtheria toxoid as the carrier.96,97,99
In postlicensure observations, adverse reactions to 
MCV4 or MPSV4 vaccines are mild and fever is infre-
quent. No adverse effects have been documented among 
women vaccinated with MPSV4 during pregnancy or among 
their newborns. There are no data available on the use of 
MCV4.99–102 Both vaccines can be administered during 
a minor acute illness, even in the presence of low-grade 
fever. Individuals sensitive to thimerosal (mercury) should 
receive preservative-free MPSV4 or MCV4 vaccines sup-
plied in the single-dose preparations. Both vaccines are 
contraindicated in persons with known hypersensitivity 
to any vaccine component or to dry natural rubber latex. 
MPSV4 can be given together with other vaccines but it 
should be administered at a different site of injection and 
with   a different syringe.96,97,99
Immunization program: strategy, 
dosing, and schedule
Disease caused by N. meningitidis has been historically 
addressed using polysaccharide vaccines against the four 
major serogroups: A, C, Y, and W-135. With few excep-
tions, polysaccharide vaccines have not been used in routine 
schedules because of perceived limitations of the duration of 
effectiveness, especially when administered during infancy. 
Given the sporadic nature of outbreaks, the optimal use 
of these vaccines to control both short-term epidemic and 
endemic disease has been the subject of much debate.103 
While developed countries have concentrated on outbreak 
control with mass vaccination strategies or prophylactic use 
for travelers, a number of countries have effectively reduced 
disease burden with routine vaccination or at school entry 
with serogroup AC polysaccharide vaccine.53,104
When deciding to implement a mass vaccination campaign 
to prevent MDC, one must consider whether the cases represent 
an outbreak or an unusual clustering of endemic cases. Mass 
vaccination programs are expensive, they require considerable 
public health effort, and they may create excessive concern 
among the public. Because the number of cases in outbreaks is 
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usually not substantial, this determination requires evaluation 
and analysis of the patterns of disease occurrence.105
An outbreak has been defined by the Centers for Disease 
Control and Prevention as the occurrence of three or more 
cases in less than 3 months, resulting in a primary disease 
attack rate of at least ten cases per 100,000 in persons who 
have a common affiliation or who live in the same area but 
have no close contact.106 Outbreaks of MD have occurred 
in organizations and communities. Mass vaccination pro-
grams to control outbreaks were an option for management 
of clusters of cases in the United States. Either MCV4 or 
MPSV4 can be used for control of outbreaks caused by a 
strain with a vaccine-preventable capsular group.73,97,106
Two MCV4s (Menactra, Sanofi Pasteur; Menveo®, 
Novartis) are licensed for use in the United States. Both 
vaccines are licensed for persons aged 2–55 years. These 
vaccines are the preferred vaccine for people aged 2–55 
years; meningococcal polysaccharide vaccine should for 
people over the age of 55 years. Approximately 7–10 days 
are required after vaccination for development of protective 
levels of antibody.107
The Advisory Committee on Immunization Practices 
(ACIP) recommends routine vaccination of persons with 
MCV4 at the age of 11 or 12 years, followed by a booster dose 
at the age of 16 years. For adolescents who receive the first 
dose at 13–15 years of age, a one-time booster dose should be 
administered, preferably at 16–18 years of age. Persons who 
receive their first dose of MCV4 at 16 years of age or older 
do not need a booster dose, unless they remain at increased 
risk for MD. Routine vaccination of healthy persons who are 
not at increased risk for exposure to N. meningitidis is not 
recommended after 21 years of age.107
Revaccination is indicated for persons who have received 
MPSV4 and who remain at high risk of MD.96 Also, persons 
previously vaccinated with either MCV4 or MPSV4 who are 
at prolonged increased risk for MD should be revaccinated 
with MCV4.107
For children who receive MPSV4 when they are under 
the age of 4 years, the ACIP recommends that revaccina-
tion be considered 2–3 years later. In addition, the ACIP 
recommends that older children and adults be considered 
for revaccination after 3–5 years. The ACIP recommends 
that revaccination of persons outside the 11- to 55-year-old 
age range should be with MPSV4.107
Data indicate that the immune response to a single dose 
of MCV4 is not sufficient in persons with certain medical 
  conditions. Persons with persistent complement component 
deficiencies or asplenia should receive a two-dose primary 
series administered 2 months apart and then receive a booster 
dose every 5 years. Adolescents aged 11–18 years with human 
immunodeficiency virus infection should be routinely vac-
cinated with a two-dose primary series. Other persons with 
human immunodeficiency virus who are vaccinated should 
receive a two-dose primary series administered 2 months 
apart. All other persons at increased risk for MD (Table 2) 
should receive a single dose. Persons previously vaccinated 
with a single dose at 7 years of age or older and who are at 
prolonged increased risk should be revaccinated 5 years after 
their previous meningococcal vaccine. Persons who previ-
ously were vaccinated with a single dose at ages 2–6 years 
and are at prolonged increased risk should be revaccinated 
3 years after their previous meningococcal vaccine.107
Public health approaches  
to patients
The function of local public health agencies is assessment, 
assurance, and policy development to promote and protect 
the health of the public. Accessibility to health services is 
critical to guarantee timely medical attention, especially 
in life-threatening diseases like MD. In most developing 
countries, health facilities lack material, drugs, and labora-
tory equipment and therefore medical attention is poor, in 
contrast to high-income countries, where medical attention 
is of a high quality and is accessible to the majority of the 
population.
MD is a compulsory notifiable disease in most   countries. 
Notification procedures must be based on the use of a stan-
dard case definition for meningococcal meningitis, with three 
recommended levels of diagnosis: suspected, probable, or 
confirmed.110 Clinicians and laboratory staff should notify 
patients rapidly, by phone or fax, to start contact tracing. 
Chemoprophylaxis can be instituted promptly.
As contagiousness of patients is moderate and disap-
pears quickly following antimicrobial treatment,   isolation 
Table 2 High-risk groups recommended for vaccination5,108,109
1 College freshmen living in dormitories
2 Microbiologists who are routinely exposed to 
isolates of Neisseria meningitidis
3 Military recruits
4 Persons who travel to or reside in countries 
where meningococcal disease is hyperendemic 
or epidemic, particularly if contact with the local 
population will be prolonged
5 Persistent complement component deficiencies  
(eg, C5–C9, properdin, factor H, or factor D)
6 People who have anatomic or functional asplenia
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of the patient is not necessary. Nevertheless, some 
  restriction measures are recommended, such as respiratory 
isolation and excluding the patient from school/institution/
work until 24 hours of an appropriate course of clearance 
antibiotic is completed.
Health education for the patient, members of the family, 
and the public is also an important concern. The patient and 
their contacts should be advised about the nature of the infec-
tion by explaining the main signs, symptoms, severity, and 
mode of transmission of disease, stressing the importance 
of treatment, vaccination, and other preventive and control 
measures.
In MD, the challenge for healthcare practitioners is to 
identify timely those patients who will progress from a 
nonspecific early presentation to severe disease, particularly 
since the early symptoms and signs may be indistinguishable 
from intercurrent and self-limiting viral infection.111 The 
majority of deaths may occur in the first 24 hours, frequently 
before the institution of specialized care.112
Current expert advice endorses the importance of effec-
tive meningococcal infection management based on early 
recognition, prompt antibiotic treatment, and speedy referral 
to hospital for all suspected cases.
If the patient is a presumptive case of MD, the case should 
be classified as high priority for assessment and review by 
the medical staff and seen urgently and receive his first dose 
of antibiotics as soon as possible.60 If a general practitioner 
(GP) decides that a patient with a nonspecific febrile ill-
ness does not require referral to a hospital, the patient must 
be under frequent and regular review, looking for clinical 
changes. If the patient subsequently develops a rash or dete-
riorates in any way, the GP should be advised or the patient 
immediately referred to a hospital emergency   department.113 
The GP should arrange urgent transfer of the patient to the 
appropriate hospital, preferably by ambulance, with para-
medics experienced in managing critically ill patients.60 MD 
is a potentially fatal disease; it should always be viewed as 
a medical emergency and it should be managed, without 
exception, in intensive care units.
Diagnosis
Clinical findings
Meningococcal infection most commonly presents as either 
meningitis or septicemia, or a combination of both. Less com-
monly, individuals may present other clinical features.5
Septicemia (also known as meningococcemia), with 
or without meningitis, can be particularly severe and has 
a fulminant and rapidly fatal course, causing MD to be a 
much-feared disease.114 The most characteristic feature of 
meningococcemia is a hemorrhagic (ie, petechial or   purpuric) 
rash that does not blanch under pressure. However, a rash is 
not always present.115 Careful attention to associated manifes-
tations such as shock and coagulopathy is critical. In nearly 
all patients who develop shock, and in most patients with 
meningitis, the beginning of the bacteremic phase is marked 
by the onset of chills, acute fever, lower back pain, thigh pain, 
or generalized muscle aches. Within a few hours, purpura 
fulminans may develop without signs of meningitis116 and 
it is often associated with the rapid onset of hypotension, 
acute adrenal hemorrhage (the Waterhouse–Friderichsen 
syndrome), and multiorgan failure.5 In children, nonspecific 
symptoms such as fever, drowsiness, nausea and vomiting, 
irritability, and poor feeding are present within 4–6 hours 
from the onset of the disease.6,111 The classic, rapidly evolving 
purpuric rash associated with MD and neck pain, or stiffness, 
usually develops after 12 hours.
Meningitis signs and symptoms depend on the age of 
the patient, the duration of illness, and the host response to 
infection. The clinical features of meningococcal meningitis 
in infants and children can be subtle, variable, nonspecific, 
or even absent. In infants, they may include hypothermia, 
lethargy, irritability, poor feeding, vomiting, respiratory dis-
tress, seizures, or bulging fontanelles.117 Unfortunately, most 
cases of MD are diagnosed after the appearance of these late 
signs, and it is not infrequent for children who are admitted 
to hospital to have been initially misdiagnosed.111
Laboratory findings
All patients with suspected meningococcal infection should 
have blood and CSF collected for Gram stain and culture. 
Aspirate or biopsy of petechiae or other skin lesions should 
also be done. PCR testing of blood (and CSF if meningitis is 
present) should be considered part of the routine diagnostic. 
Nevertheless, the classic laboratory diagnosis of MD has 
relied on bacteriologic culture, but the sensitivity of culture 
may be low, especially when performed after the initiation 
of antibiotic treatment.
Since CSF examination is of paramount importance 
for the diagnosis of meningococcal meningitis, lumbar 
puncture is essential.110 CSF is usually turbid or purulent 
(but may occasionally be clear or bloody). Basic routine 
  examination feasible in most laboratories consists of 
measurement of the white blood cell count (usually 
above 1000 cells/mm3 with .60% polymorphonuclears; 
  measurement of   protein level: .0.80 g/L and Gram stain, 
showing intra- or extracellular Gram-negative diplococci. 
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Diagnosis is confirmed by the isolation of N. meningitidis, the 
demonstration of Gram-negative diplococci, or the detection 
of meningococcal antigen in CSF, blood, or other normally 
sterile site.110 PCR analysis offers the advantages of detecting 
serogroup-specific N. meningitidis DNA and of not requiring 
live organisms for a positive result.5
CSF culture can be negative in patients who receive anti-
biotic treatment before CSF examination.118 In such patients, 
increased white blood cell counts and protein concentration in 
CSF are usually sufficient to establish presumptive diagnosis. 
Blood cultures or non-culture diagnostic tests may help in 
identifying the infecting pathogen, especially in septicemia. 
Non-culture tests should be considered for patients who need 
earlier identification of pathogens, who have previously 
received antibiotics, or whose initial CSF Gram stain is 
negative. Such tests mainly include latex agglutination, PCR, 
loop-mediated isothermal amplification method, microarray 
or biochip, and immunochromatography.118
Treatment
Timing
In MD, the speed with which treatment is initiated, antibiotics 
are administered, and complications of shock and multiorgan 
failure are treated is a major determinant of outcome. The 
duration of delay in initiating antibiotic therapy after hospi-
tal admission and suboptimal health care delivery has been 
directly associated with poor outcome.119–121
Intensive care management
The primary goals of therapy in the first hours following clini-
cal presentation are to maintain oxygenation and ventilation 
and to achieve normal tissue perfusion. Early semielective 
intubation and positive-pressure mechanical ventilatory sup-
port should be strongly considered in this setting. Circulation 
is the next target to assess and manage.122 In addition, myocar-
dial support with inotropes is frequently necessary to maintain 
end organ perfusion in more severely ill patients.123 An increas-
ingly recognized approach is an effort to rapidly stabilize the 
hemodynamics using early goal-directed therapy.122 In adults, 
early goal-directed therapy aims at achieving adequate central 
venous pressure, mean arterial pressure, urine output, and 
central venous oxygenation within 6 hours.124 Dopamine 
remains the most common first choice of inotropic agents 
for patients with fluid-refractory shock, but both reported 
and theoretical adverse effects include functional suppres-
sion of neutrophils by attenuating the chemoattractant effect 
of interleukin-8 and interference with the neuroendocrine 
system by suppressing the release of many anterior pituitary 
hormones, including growth hormone, thyroid-stimulating 
hormone, and prolactin, aggravating immune dysfunction 
and increasing susceptibility to infection.125,126 Therefore, 
clinicians are increasingly choosing low-dose epinephrine to 
achieve beta-adrenergic-mediated inotropic support as a first-
line therapy for fluid refractory shock. Epinephrine stimulates 
gluconeogenesis and glycogenolysis and inhibits the action of 
insulin, leading to an adverse profile of dysregulated serum 
glucose also increasing the production of lactate, independent 
of organ perfusion. Other inotropic agents used are milrinone 
and vasopressin.122
It is important to note that resuscitation end points 
targeted in resource-rich health care environments are not 
available to intensive care personnel in many developing 
parts of the world. As a result, these practitioners rely on 
clinical therapeutic end points: normalization of heart rate, 
capillary refill time ,2 seconds, strong peripheral pulses, 
warm extremities, normal blood pressure, return to baseline 
mental status and normal respiratory rate.122 In severe MD, 
microthrombosis and hypoperfusion can lead to extensive 
purpura (mainly in limbs or skin) that can become necrotic. 
Extensive necrotic areas can consume clotting factors, 
worsen any coagulopathy, and serve as reservoir for bacteria, 
leading to prolonged bacteremia.6
Early fluid resuscitation is associated with improved 
survival.123 In the intensive care unit, large amounts of fluids 
may be required during the first days of care, and vasoactive 
drug infusions are often needed. Coagulopathy is frequent, but 
it has no specific treatment. The use of colloids and steroids 
may be beneficial, but other new therapies such as insulin 
and activated protein C still need to be studied further. When 
present, cerebral edema and altered cerebral blood flow are the 
main concerns; the use of osmolar solutions may be necessary, 
but the main therapeutic intervention is to ensure adequate 
blood pressure for adequate cerebral perfusion.   Seizures and 
hyponatremia should be aggressively treated.6
Choice of antimicrobials
Antibiotics are considered a cornerstone of MD treatment 
and must be instituted as soon as possible. In patients with 
suspected meningococcal meningitis for whom immediate 
lumbar puncture is delayed because of pending brain imaging 
study or the presence of disseminated intravascular coagula-
tion, blood cultures must be obtained and empirical antimicro-
bial treatment should be initiated immediately with parenteral 
antibiotics (either benzylpenicillin or cefotaxime).118,127
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The choice of which antibiotic to use should be made 
based on local antibiotic resistance and availability. Many 
antimicrobials are active against meningococci in vitro, but 
only those that penetrate sufficiently the cerebrospinal space 
and are affordable should be used. Either parenteral ampicil-
lin or penicillin is the drug of choice.6,111 Chloramphenicol is 
a good and inexpensive alternative. Third-generation cepha-
losporins (ceftriaxone and cefotaxime) are excellent alterna-
tives, but they are considerably more expensive. Although 
oral cotrimoxazole (trimethoprim-sulfamethoxazole) is inex-
pensive and has good CSF penetration, sulfa-resistant strains 
have become common and sulfa drugs are not recommended 
unless sulfa-sensitivity testing has been done. In unfavorable 
conditions, the drug of choice is oily chloramphenicol.110
Route of administration
The intravenous route is recommended. However, a series 
of clinical studies have shown the use of intramuscular 
chloramphenicol in oil to be as effective as intravenous 
ampicillin for MD.110
Duration of antibiotic therapy
A 7-day course is still the rule for the treatment of 
MD (beyond the neonatal period) in most high-income 
  countries.110 However, there is good evidence that for menin-
gococcal meningitis a 3- or 4-day course of benzylpenicillin 
is as effective as any longer course of antimicrobials.128 The 
long-acting form of chloramphenicol has also been shown 
to be effective.110
As well as antibiotics, high-level intensive care support-
ive therapy should be used where medically appropriate. 
Particular attention should be paid to maintenance of blood 
pressure and tissue perfusion and management of cerebral 
edema. Patients may require artificial ventilation and other 
forms of support for prolonged periods, and the complications 
of the coagulopathy, or intravascular coagulation abnormali-
ties, may be severe.60
Although patients with MD are not efficient transmit-
ters of meningococci, the failure to administer appropriate 
clearance antibiotics in patients treated with penicillin is not 
acceptable, and the public health response should include 
advice to treating physicians on the use of clearance antibiot-
ics when appropriate.96
Adjunctive treatment
The beneficial effect of adjunctive dexamethasone   treatment 
has been reported by various authors.129 In a 2007 Cochrane 
review, adjunctive treatment with dexamethasone was 
  associated with lower case mortality, and lower rates of 
severe hearing loss and long-term neurological sequelae, but 
concerns have been expressed about reducing blood-brain 
permeability and thereby the penetration of antibiotics in the 
subarachnoid space.130 The use of steroids in the treatment 
of MD is still controversial and remains a topic of debate.
Physical sequelae
Improvement in intensive care and supportive therapy, 
increased the number of survivors of MDC that may sub-
sequently suffer from severe physical sequelae. Affected 
patients need long-term multidisciplinary rehabilitation, as 
there can be a significant reduction in functional ability and 
quality of life.10,131,132 The severity of invasive disease and 
physical disability may be greater in patients with MDC than 
in those with MD caused by serogroup B.10,132–135
In cases with septicemia and peripheral ischemia, 
surgical management should be carried out immediately. 
Early microsurgical arteriolysis is a reliable method for 
reducing the number of devastating amputations normally 
found in some patients with meningococcal sepsis. This 
significantly improves the functional outcome in severely 
ischemic limbs.136 When there is peripheral ischemia in the 
presence of raised pressures in the lower limb, fasciotomy is 
indicated if the rash has been present for less than 24 hours 
and there is no contraindication such as excessive bleeding. 
Amputation should be delayed since the end result may not 
be predictable (at initial presentation) and should be carried 
out as an elective procedure with the aim of giving the child 
a stump for life. It should be carefully planned and expertly 
carried out.137
Conclusion and future directions
Worldwide, MDC continues to be an important cause of mor-
bidity, mortality, and neurological sequelae and it continues 
to require high levels of public health spending. Each country 
should determine the measures most adequate to prevent and 
control the disease according to that country’s epidemiology, 
the most feasible public health approaches, and the existing 
economic support. The health policy in each country should 
consider current behavior of disease, immunogenicity and 
antibody protection persistence in high-risk groups after 
immunization, vaccine effectiveness, and the costs and ben-
efits of different strategies. Improvement of surveillance to 
monitor changes in disease epidemiology and to evaluate the 
impact of available and future vaccines is essential.
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